<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840121</url>
  </required_header>
  <id_info>
    <org_study_id>IIS - 1006</org_study_id>
    <nct_id>NCT04840121</nct_id>
  </id_info>
  <brief_title>Personalizing Window of Implantation During Frozen Embryo Transfer</brief_title>
  <acronym>AdhesioRT</acronym>
  <official_title>ADHESIORT - Personalizing Window of Implantation During Frozen Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Ovo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinique Ovo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Embryo implantation is a crucial event in the establishment of a pregnancy. Although the&#xD;
      clinical and culture conditions to obtain a &quot;good quality&quot; embryo are well advanced today,&#xD;
      endometrial receptivity remains a major barrier in assisted reproductive techniques. Once a&#xD;
      high-quality embryo is transferred, impaired uterine receptivity is believed to be one of the&#xD;
      major reasons behind failure of the establishment of pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized in either the study group - AdhesioRT or in the control group - standard of care. All participants recruited, including the control group, will have the AdhesioRT biopsies performed.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of appropriate window of implantation</measure>
    <time_frame>14 days after embryo transfer</time_frame>
    <description>Comparison between standard frozen embryo transfer and personalized frozen embryo transfer using AdhesioRT to determine a successful window of implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical pregnancy</measure>
    <time_frame>14 days after embryo transfer</time_frame>
    <description>Blood test to determine if the embryo transfer was successful or not</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Fertility</condition>
  <arm_group>
    <arm_group_label>Study Group - AdhesioRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the study group will proceed with frozen embryo transfer cycle according window of implantation determined by AdhesioRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group - Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the control group will proceed with the first frozen embryo transfer cycle as per standard of care. In the event of unsuccessful implantation (negative serum pregnancy test), participants will proceed with subsequent frozen embryo transfer cycle according to window of implantation determined by AdhesioRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>AdhesioRT</intervention_name>
    <description>AdhesioRT, a novel diagnostic genetic assay, developed by ovo R&amp;D scientists, helps to predict the endometrial receptivity and embryo implantation.</description>
    <arm_group_label>Control Group - Standard of Care</arm_group_label>
    <arm_group_label>Study Group - AdhesioRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between the ages of 18 to 40 inclusive at the time of oocyte retrieval&#xD;
&#xD;
          -  Prescription of a single frozen embryo transfer - substituted cycle protocol&#xD;
&#xD;
          -  Participant has at least 2 vitrified good quality blastocysts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women undergoing fertility preservation&#xD;
&#xD;
          -  Stage IV severe endometriosis&#xD;
&#xD;
          -  Severe malformation, adenomyosis or uterine anomaly including fibroids deforming the&#xD;
             uterine cavity â‰¥ 5 cm&#xD;
&#xD;
          -  Positive results of screening for either participant or partner for HIV antibodies,&#xD;
             Hepatitis B (other than surface antibodies present after vaccination) or Hepatitis C&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isaac-Jacques Kadoch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Ovo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Leblanc, RN</last_name>
    <phone>5147982000</phone>
    <phone_ext>617</phone_ext>
    <email>s.leblanc@cliniqueovo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Ovo</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelly Delouya, RN</last_name>
      <phone>5147982000</phone>
      <email>n.delouya@cliniqueovo.com</email>
    </contact>
    <investigator>
      <last_name>Isaac-Jacques Kadoch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

